Re: Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer

被引：10
|
作者：
Nielsen, Torsten O.
Cheang, Maggie C. U.
Chia, Stephen K.
Voduc, David
Gao, Dongxia
Leung, Samuel
Bernard, Philip S.
Perou, Charles M.
Ellis, Matthew J.
机构：
来源：
JOURNAL OF THE NATIONAL CANCER INSTITUTE | 2009年 / 101卷 / 24期
关键词：
ESTROGEN-RECEPTOR;
D O I：
10.1093/jnci/djp390
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1730 / 1730
页数：1
相关论文
共 50 条
  • [31] Ki67 expression and the effect of neo-adjuvant chemotherapy on luminal HER2-negative breast cancer
    Yoshiya Horimoto
    Atsushi Arakawa
    Masahiko Tanabe
    Hiroshi Sonoue
    Fumie Igari
    Koji Senuma
    Emi Tokuda
    Hideo Shimizu
    Taijiro Kosaka
    Mitsue Saito
    BMC Cancer, 14
  • [32] Conversion of ER, PR, HER2 and Ki-67 and Prognosis in breast cancer metastases to the brain
    Jiaxin, Chen
    Jinmei, Zhou
    Huiqiang, Zhang
    Xuexue, Wu
    Xiaobo, Wang
    Shaohua, Zhang
    Yanhong, Tai
    Zefei, Jiang
    Tao, Wang
    FRONTIERS IN NEUROLOGY, 2022, 13
  • [33] Ki67 measured in metastatic tissue and prognosis in patients with advanced breast cancer
    Falato, Claudette
    Lorent, Julie
    Tani, Edneia
    Karlsson, Eva
    Wright, Paul K.
    Bergh, Jonas
    Foukakis, Theodoros
    BREAST CANCER RESEARCH AND TREATMENT, 2014, 147 (02) : 407 - 414
  • [34] Ki67 in Breast Cancer: The Effect of Different Length of Fixation on Ki 67 Index
    Faragalla, H. F.
    Feeley, L.
    Bane, A.
    Mulligan, A. M.
    LABORATORY INVESTIGATION, 2013, 93 : 40A - 40A
  • [35] Combined quantitative measures of ER, PR, HER2, and KI67 provide more prognostic information than categorical combinations in luminal breast cancer
    Abubakar, Mustapha
    Figueroa, Jonine
    Ali, H. Raza
    Blows, Fiona
    Lissowska, Jolanta
    Caldas, Carlos
    Easton, Douglas F.
    Sherman, Mark E.
    Garcia-Closas, Montserrat
    Dowsett, Mitch
    Pharoah, Paul D.
    MODERN PATHOLOGY, 2019, 32 (09) : 1244 - 1256
  • [36] The Ki67 Index as a Prognostic Marker in Primary Hormone Receptor Positive/Her2 Negative Lumina! Breast Carcinoma
    El-Gendi, Saba
    Talaat, Iman
    Abu-Sheasha, Ghada
    MODERN PATHOLOGY, 2017, 30 : 40A - 41A
  • [37] Immunocytochemical results for HER2 and Ki67 in breast cancer touch-smear cell specimens are reliable
    Masami Morimoto
    Yoshimi Bando
    Misako Nakagawa
    Hirokazu Takechi
    Takahiro Yoshida
    Junko Honda
    Yukiko Tadokoro
    Takuya Moriya
    Mitsunori Sasa
    Akira Tangoku
    Breast Cancer, 2016, 23 : 577 - 582
  • [38] Conventional and digital Ki67 evaluation and their correlation with molecular prognosis and morphological parameters in luminal breast cancer
    Pons, Laura
    Hernandez-Leon, Laura
    Altaleb, Ahmad
    Ussene, Esperanca
    Iglesias, Roman
    Castillo, Ana
    Rodriguez-Martinez, Paula
    Castella, Eva
    Quiroga, Vanesa
    Felip, Eudald
    Cirauqui, Beatriz
    Margeli, Mireia
    Fernandez, Pedro Luis
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [39] Effects of neoadjuvant trastuzumab, pertuzumab and palbociclib on Ki67 in HER2 and ER-positive breast cancer
    Luca Gianni
    Marco Colleoni
    Giancarlo Bisagni
    Mauro Mansutti
    Claudio Zamagni
    Lucia Del Mastro
    Stefania Zambelli
    Giampaolo Bianchini
    Antonio Frassoldati
    Ilaria Maffeis
    Pinuccia Valagussa
    Giuseppe Viale
    npj Breast Cancer, 8
  • [40] Prognosis related to Ki67 in early breast cancer.
    Gerson, R.
    Alban, F.
    Villalobos, A.
    Serrano, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345